After RBC Capital and Robert W. Baird gave Neurocrine (NASDAQ: NBIX) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst Sumant Kulkarni maintained a Buy rating on Neurocrine yesterday and set a price target of $127.00. The company’s shares closed last Monday at $103.10.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of 6.9% and a 46.8% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Zynerba Pharmaceuticals.
Neurocrine has an analyst consensus of Strong Buy, with a price target consensus of $126.22, implying a 24.8% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $126.00 price target.
See today’s analyst top recommended stocks >>
Based on Neurocrine’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $34 million. In comparison, last year the company had a net profit of $18.08 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.
